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Soy Isoflavones Augment Radiation Effect by Inhibiting
APE1/Ref-1 DNA Repair Activity in Non-small Cell Lung
Cancer
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Fazlul H. Sarkar, PhD,† Steven Miller, MD,* Shirish M. Gadgeel, MD,‡ Andre A. Konski, MD,*
and Gilda G. Hillman, PhD*
Introduction: Soy isoflavones sensitize cancer cells to radiation
both in vitro and in vivo. To improve the effect of radiotherapy for
non-small cell lung cancer, we assessed the potential of using a
complementary approach with soy isoflavones.
Methods: Human A549 non-small cell lung cancer cells were
treated with soy isoflavones, radiation, or both and tested for cell
growth. DNA double-strand breaks (DSBs) were detected by immu-
nostaining for -H2AX foci. Expressions of -H2AX, HIF-1, and
APE1/Ref-1 were assessed by Western blots. DNA-binding activi-
ties of HIF-1 and NF-B transcription factors were analyzed by
electrophoretic mobility shift assay.
Results: Soy isoflavones increased A549 cell killing induced by
radiation. Multiple -H2AX foci were detectable at 1 hour after
radiation but decreased at 24 hours after radiation. Soy isoflavones
also caused DNA DSBs, but -H2AX foci increased over time. Soy
isoflavones and radiation caused an increase in -H2AX foci, which
persisted at 24 hours, indicating both increased DNA damage and
inhibition of repair. Soy isoflavones inhibited the radiation-induced
activity of the DNA repair/redox enzyme APE1/Ref-1 and the
transcription factors NF-B and HIF-1. E3330, which inhibits the
redox activity of APE1/Ref-1, did not alter the repair of radiation-
induced DSBs. Methoxyamine, which inhibits APE1/Ref-1 DNA
repair activity, partly blocked the decrease in radiation-induced
DSBs at 24 hours, suggesting partial mitigation of radiation-induced
DNA repair akin to the effect of soy combined with radiation, in
agreement with cytotoxic assays.
Conclusions: Inhibition of APE1/Ref-1 DNA repair activity by soy
could be involved in the mechanism by which soy alters DNA repair
and leads to cell killing.
Key Words: Lung cancer, Soy isoflavones, Radiation, -H2AX,
APE1/Ref-1.
(J Thorac Oncol. 2011;6: 688–698)
Lung cancer is the most common malignancy in both menand women in the United States and the leading cause of
death. It is estimated that more than 215,000 people/yr will be
diagnosed with lung cancer.1 Approximately 85% of lung
cancers are classified as non-small cell lung cancer (NSCLC),
which includes squamous cell carcinoma, adenocarcinoma,
and large cell carcinoma. Standard therapy for stage 1
(T1-2N0M0) NSCLC is surgical treatment, resulting in
5-year survival rates of 60 to 70%. Nevertheless, in some of
the patients who have early-stage NSCLC, the cancer is
considered inoperable because the patient is unable to un-
dergo surgery due to chronic obstructive pulmonary disease
and cardiac disease. The standard treatment for these patients
has traditionally been thoracic radiotherapy (RT), using frac-
tionated doses to a total of approximately 60 Gy delivered
daily during a period of 5 to 6 weeks. RT achieves local
control in less than 30% of early-stage patients.2
Stereotactic body radiotherapy (SBRT) is a promising
technology, which is emerging as a new treatment for patients
with early-stage peripheral NSCLC who cannot undergo
surgical resection of their lesion. SBRT delivers multiple
beams of high-dose radiation to a highly conformal-specific
target and is given in 5 or less fractions. The dose per fraction
of 12 to 20 Gy with SBRT is much greater than the doses of
1.8 to 2 Gy per fraction delivered with conventional RT.
Overall treatment time is significantly reduced to 1 to 2 weeks
with SBRT versus 6 to 7 weeks with conventional RT. These
characteristics of SBRT make it not only more effective than
conventional RT in the treatment of early-stage cancer but
also potentially more damaging to normal lung tissue.3,4
To improve the effect of SBRT on the tumor target and
reduce the radiation dose-limiting toxicity of SBRT to the
normal lung, we have explored the potential for biological
intervention using soy isoflavones in combination with RT
for NSCLC. The rationale for selecting soy isoflavones to
combine with SBRT is based on our work demonstrating that
these compounds not only cause tumor cell apoptosis but also
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sensitize cancer cells to radiation both in vitro5–10 and in vivo
in preclinical orthotopic models of prostate cancer and renal
cell carcinoma.7,8,10–14 We have shown that the mixture of
soy isoflavones or pure genistein inhibited cell growth and
potentiated radiation-induced cell killing of human prostate
cancer cell lines PC-3 and C4-2B cell in vitro.5–10 This effect
was also observed with human renal cell carcinoma and
breast cancer cell lines.6 Moreover, we found that the mech-
anisms of potentiation of RT by soy isoflavones involve the
inhibition of radiation-induced activation of survival signal-
ing pathways both in vitro and in vivo in PC-3 prostate
tumors in mice.6–10,14 We have identified three molecular
targets APE1/Ref-1, NF-B, and HIF-1, which were acti-
vated by tumor cells, as a survival response to radiation but
were inhibited by soy isoflavones, resulting in enhanced cell
killing and tumor growth inhibition.7,9,10 APE1/Ref-1 is a
protein involved in DNA repair and redox activation of
transcription factors including NF-B and HIF-1.14 Not
only are these natural soy isoflavones safe and nontoxic
anticancer agents, as demonstrated in controlled clinical tri-
als,15 but they can also act as antioxidants in normal tissues
and protect them from treatment toxicity.16 This protective
effect was observed in our clinical trial for patients with
prostate cancer, which showed that soy isoflavones pills,
taken in conjunction with RT, reduced radiation toxicity
resulting in improved urinary, gastrointestinal, and sexual
functions.17
In lung cancer, a prospective cohort study in Japan
showed that soy isoflavones intake was associated with a
decreased risk of lung cancer in nonsmokers.18 We have
previously reported that pure genistein demonstrated antitu-
mor activity in human NSCLC cell lines and enhanced the
effects of epidermal growth factor receptor (EGFR)-tyrosine
kinase inhibitors.19 In this study, we have investigated the effect
of soy alone and combined with radiation on the growth of
human NSCLC cells in vitro. These studies were performed
with a formulation of soy consisting of a mixture of the main
three isoflavones found in soybeans, which include genistein,
daidzein. and glycitein.8,10 This formulation is consistent with
the soy isoflavones pills used in clinical studies and has proven
to be safe.20 In addition, the soy mixture showed a greater
antitumor effect in vitro and in vivo than pure genistein in our
previous studies and did not cause increased metastasis in
orthotopic animal models in contrast to pure genistein.8,11–13
In this study, we report that soy isoflavones could
inhibit the growth of NSCLC cells in a dose-dependent
manner and potentiated radiation-induced cell killing. These
data were consistent with increased DNA double-strand
breaks (DSBs) formation induced by radiation combined with
soy isoflavones. Ionizing radiation causes rapid phosphory-
lation of the nucleosomal histone protein H2AX at Ser 139
(-H2AX), occurring at sites of DNA DSBs, which can be
visualized as fluorescent foci by immunostaining.21,22 In-
creased DNA damage was also consistent with soy-mediated
inhibition of APE1/Ref-1 up-regulation induced by radiation,
thus blocking this DNA repair mechanism. Soy isoflavones
also inhibited the radiation-induced expression and activity of
the transcription factors NF-B and HIF-1, probably driving
lung cancer cells to death pathways rather than survival
pathways.
MATERIALS AND METHODS
Tissue Culture
The human non-small cell lung carcinoma (NSCLC)
A549 and H1650 cell lines were purchased from ATCC
(Manassas, VA) and grown in F-12K culture medium (CM)
containing 7% heat-inactivated fetal bovine serum with sup-
plements.
Tumor Cell Growth Assays and Clonogenic
Analysis of Cell Survival
The soy isoflavones mixture G-4660 consisted of
83.3% genistein, 14.6% daidzein, and 0.26% glycitein (man-
ufactured by Organic Technologies (Coshocton, OH) and
obtained from National Institutes of Health). Soy isoflavones
were dissolved in 0.1 mol/L Na2CO3 and further diluted in
CM to obtain final concentrations of 5 to 100 mol/L.7,10
Control cells were incubated with equivalent dilutions of
Na2CO3 in CM. Radiation treatment was done with an x-ray-
generating Pantak HF 320 instrument with settings at 320kV,
10 mA, at 0.9 Gy/min. For cell count assays, A549 cells
were plated at 105 cells/well in duplicate wells, in six-well
plates.10 A day later, cells were treated with doses of 10 to
100 M soy isoflavones or irradiated at doses of 1 to 8 Gy.
After 96-hour incubation, viable cells were counted using
trypan blue exclusion dye.10 For clonogenic assays, the num-
ber of cells plated per treatment group was determined based
on cell titration experiments to predict a measurable survival
fraction at different soy isoflavones and/or radiation doses.
To measure the survival fraction after soy isoflavones treat-
ment, A549 cells were treated with 5 to 30 M of soy
isoflavones for 24 hours, and then cells were plated in
triplicate wells in six-well plates in 2 ml CM as follows: 500
cells/well for control and 5 M soy isoflavones; 1000 cells
for 7.5 M soy isoflavones; 2000 cells for 10 and 15 M soy
isoflavones; and 3000 cells for 20, 25, and 30 M soy
isoflavones.6–8,10 To determine the radiosensitivity of A549,
cells were irradiated with 1 to 10 Gy doses and replated in
triplicate wells in six-well plates in 2 ml CM as follows: 500
cells/well for control; 1000 for 1 Gy; 2000 for 2 or 3 Gy;
4000 for 4 or 5 Gy; 5000 for 6 Gy; 6000 for 7 or 8 Gy; and
8000 for 9 or 10 Gy. For combined soy isoflavones/radiation
treatment, cells were pretreated with soy isoflavones for 72
hours, then irradiated with 3 Gy and plated at 500 cells/well
for control or 5 M soy isoflavones, 1000 cells for 10 M
soy isoflavones or 3 Gy radiation, 2000 cells for 3 Gy
radiation  5 M soy isoflavones, and 3000 cells for 3 Gy
radiation  10 M soy isoflavones.6–8,10 Plates were incu-
bated for 10 days at 37°C in a 5% CO2/5% O2/90% N2
incubator. For treatment groups including soy isoflavones,
colony plates were supplemented with soy isoflavones. Col-
onies were fixed and stained using 2% crystal violet, and
colonies with 50 cells were counted. The plating efficiency
was calculated for each well by dividing the number of
colonies by the original number of cells plated. The surviving
fraction (SF) was normalized to control cell plating efficiency
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by dividing the plating efficiency of treated cells by that of
control cells.6–8,10
Western Blot Analysis
For Western blot analysis, total cell protein extract
(20–40 g) or nuclear fraction (5–6 g) samples were
loaded and separated on 7.5%, 10%, or 12% sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred to Trans-Blot membranes (Bio-Rad, Hercules,
CA). Membranes were immunoblotted with primary antibod-
ies (Abs) directed against HIF-1 (R&D systems, Minneap-
olis, MN), APE1/Ref-1 (Novus Biologicals, Littleton,
CO),7,9,10 and phosphorylated H2AX at Ser 139 (-H2AX)
(Millipore, Kankakee, IL).21 Abs were diluted in a range of
1:500 to 1:2500. Membranes were incubated in IgG-HRP
secondary Abs. Membranes were reprobed with anti--actin
Ab or retinoblastoma Ab (Santa Cruz, Santa Cruz, CA) as an
internal control. Membranes were incubated in SuperSignal
West Pico Chemiluminescent Substrate and analyzed in Bio-
Rad ChemiDoc XRS imaging system.7,9,10
-H2AX Immunofluorescence Staining of Cells
Cells were cultured onto cover slips in six-well plates
and treated with 30 M soy isoflavones for 24 hours, then
irradiated with 3 Gy. At 1 hour and 24 hours after radiation,
cells were fixed with 2% formaldehyde, permeabilized with
0.5% Triton X100, and incubated 1 hour at room temperature
with anti--H2AX Ab.23,24 After washing with phosphate-
buffered saline, cells were exposed for 2 hours to Alexa Fluor
594-conjugated goat antimouse secondary Abs (Invitrogen,
Carlsbad, CA) prepared in 4,6-diamidino-2-phenylindole
(DAPI) and 0.05% Triton X 100. Fluorescent images were
captured using a Nikon Eclipse E-800 UV microscope for
detection of DAPI and Alexa Fluor staining, and foci were
counted.24 Composite images consisting of DAPI (blue staining
of nuclei) and -H2AX foci (red staining) were analyzed using
Image-ProPlus version 6.2 software (MediaCybernetics).
Briefly, cell outlines were established for each image by blue-
channel extraction and manual histogram-based segmentation.
Foci were counted within these outlines using red-channel ex-
traction and a 5  5 Laplace edge enhancement filter followed
by manual histogram-based segmentation. The number of foci
per cell, the total number of foci per 400 field, and the number
of cells positive and negative for -H2AX per 400 field were
obtained (Table 2). These experiments were repeated in the
presence of APE1/Ref-1 inhibitors including E3330 and me-
thoxyamine (Sigma-Aldrich, St. Louis, MO).
Electrophoretic Mobility Shift Assay
Nuclear extracts were prepared from treated cells
using a Sigma CelLytic NuCLEAR Extraction Kit (Sigma-
Aldrich). Electrophoretic mobility shift assay (EMSA) was
accomplished as previously detailed. Briefly, 5 g of nuclear
proteins were incubated with IRDye-700-labeled NF-B oli-
gonucleotides or IRDye-700-labeled HIF-1 oligonucleo-
tides (LI-COR Biosciences, Lincoln, NE).7,9,10 The DNA-
protein complex was run on 8% native polyacrylamide gel
using TBE buffer, pH 8.4. The bands were visualized by
Odyssey Infrared Imaging System. AlphaEaseFC imaging
software (AlphaInnotech) was used to quantify resultant
bands, and results are shown as the mean integrated density
value (I.D.V.) of the band/g protein loaded.7,9,10 Equal
protein loading was ensured by immunoblotting 10 g of
nuclear protein with retinoblastoma Ab.
Statistical Analysis
Comparisons between means of various treatment groups
in cell growth and clonogenic assays, and Western blot
analysis and EMSA were analyzed by two-tailed unpaired
Student’s t test.7,9,10
RESULTS
Soy Isoflavones Enhance Radiation-Induced
Cell Killing of A549 Cells
The short-term effect of doses of 10 to 100 M of the
soy mixture on cell growth was assessed by counting viable
cells after 96-hour treatment in vitro. Soy isoflavones inhib-
ited cell growth in a dose-dependent manner (Figure 1A).
Compared with control cells, inhibition of 40% in cell growth
was observed with 25 M and was greater than 80% at doses
50 M (p  0.001) (Figure 1A). A dose-dependent radia-
tion response was also observed with 50% inhibition in cell
growth at a dose of 3 Gy and 80% at a dose of 8 Gy (p 
0.001) (Figure 1B).
The long-term effect of soy and/or radiation on cell
killing was assessed using clonogenic assays. Based on cell
growth data, we tested a lower range of 5 to 30 M soy
isoflavones. Soy isoflavones at 25 and 30 M caused almost
complete cell killing, whereas at lower concentrations (10
and 15 M), a significant reduction of 40 to 60% in cell
survival was observed (p  0.001). No significant effect was
mediated by 5 and 7.5 M soy isoflavones (Figure 2A). In
radiation dose titration clonogenic assays, a significant inhi-
bition in colony formation was observed already at a radiation
dose of 2 Gy and was further increased at higher radiation
doses (Figure 2B). The SF curve fitted the linear-quadratic
model with an / ratio of 5 Gy and an SF2 of 0.46,
indicating that A549 cells are relatively radiosensitive (Figure
2B, inset).
Based on the soy isoflavones and radiation titration
clonogenic assays, cells were pretreated with low soy isofla-
vones concentrations of 5 to 10 M and then irradiated with
3 Gy x-rays. Cells were plated in clonogenic assays and
supplemented with soy isoflavones. A further decrease in
survival fraction resulting in 90% cell killing was observed
when radiation was combined with soy isoflavones treatment
at each low dose tested including 5, 7.5, and 10 M com-
pared with radiation alone (p  0.05) and to soy isoflavones
alone (p 0.001) (Figure 2C). Even though the dose of 5 M
soy isoflavones had no effect on A549 cell survival, it
augmented the killing effect of radiation. To address whether
this effect is synergistic or additive, the survival fraction of
soy isoflavones treatment at 5, 7.5, and 10 Mwas multiplied
by the survival fraction of 3 Gy radiation, and their products
were compared with the value of the survival fraction of cells
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treated with combined soy and radiation.25 These data show
that in each concentration of soy isoflavones tested, the
products of the survival fractions of each treatment alone
[SF(S)  SF (R)] was greater than that of the combined soy
and radiation treatment [SF(S  R)], indicating that this
effect could be synergistic (inset in Figure 2C). In an inde-
pendent experiment, using a dose of 2 Gy radiation combined
with 5 and 7.5 M soy isoflavones, we also found that
[SF(S)  SF (R)] was greater than [SF(S  R)], confirming
our observations with 3 Gy radiation (data not shown).
We also tested whether the enhanced killing by soy
combined with radiation in A549 lung cancer cells was
reproduced in an additional human lung cancer cell line
H1650. A short-term cell growth assay showed that inhibition
of cell growth was significantly greater when 10 or 25 M of
soy isoflavones were combined with 3 Gy radiation than that
by treatment with soy isoflavones alone or radiation alone
(p  0.05) (Table 1).
Soy Augments Radiation-Induced DNA
Damage in A549 Cells
To assess the effect of soy and radiation on DNA, the
formation of DSBs was measured by immunostaining of
-H2AX. A549 cells were pretreated with soy isoflavones (30
M) for 24 hours and then irradiated at 3 Gy. After incuba-
tion for 1 hour and 24 hours after radiation, corresponding to
24 and 48 hours treatment with soy isoflavones, respectively,
cells were processed for -H2AX immunostaining. Represen-
tative sections of 400 images are shown in Figure 3, and the
quantitative data analysis of -H2AX foci is presented in
Table 2. The majority of control cells were negative, whereas
approximately 40 to 50% of the cells treated with soy isofla-
FIGURE 1. A549 cell growth inhibition by soy
isoflavones and radiation. A, Soy dose titration.
Cells were treated for 4 days with soy at concen-
tration of 0, 10, 25, 50, 75, and 100 M, and
viable cells were counted. B, Radiation dose titra-
tion. Cells were irradiated with doses of 1, 2, 3, 5,
6, and 8 Gy, and viable cells were counted. Bars
represent the mean number of cells of duplicate
wells calculated as the percentage of control
cells  SE. *p  0.001 relative to control group.
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vones showed several -H2AX foci at 24-hour treatment
(p  0.001) (Figure 3; Table 2). Cells treated with soy
isoflavones for 48 hours showed a significant increase greater
than twofold in the number of -H2AX foci and a greater
frequency of 60 to 70% cells positive for -H2AX foci
(-H2AX) compared with 24 hours (p  0.001). At 1 hour
after 3 Gy radiation, 80 to 90% of the cells were -H2AX
with multiple foci compared with control (p  0.001) or soy
isoflavones-treated cells (p  0.001) (Figure 3; Table 2).
Nevertheless, when irradiated cells were further incubated up
to 24 hours after radiation, there was a dramatic decrease in
the mean number of foci per cell (from approximately 14 to
FIGURE 2. Survival fraction of A549 cells treated
with soy and/or radiation. A, Survival of cells
treated with soy. A549 cells were treated for 72
hours with soy at concentrations of 5, 7.5, 10,
15, 20, 25, and 30 M and plated in a clono-
genic assay. B, Survival of cells treated with radia-
tion. A549 cells were irradiated with different
doses of 1 to 10 Gy and plated in a clonogenic
assay. Inset: the radiation dose survival curve is
fitted by a nonlinear least-square regression ac-
cording to the linear-quadratic formula (SAS
JMPV7). C, Survival of cells treated with soy and
radiation. A549 cells were pretreated with soy at
5, 7.5, and 10 M for 72 hours, then irradiated at
3 Gy and plated in a clonogenic assay in the pres-
ence of the same concentration of soy. Inset in
(C) shows the products of SF(S) and SF(R), which
are the survival fraction of soy treatment at 5, 7.5,
and 10 M multiplied by the survival fraction of 3
Gy radiation SF(R). These products are greater
than the survival fraction of cells treated with
combined soy and radiation [SF(S  R)] at each
concentration of soy tested. In panels A, B, and C,
bars represent the mean survival fraction of tripli-
cate wells  SE. *p  0.001 represent significance
of each treatment group relative to control group.
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1), the total number of -H2AX per field (from 693 to 59), and
in the frequency of -H2AX cells (from 87 to 15%) compared
with 1 hour after radiation (p  0.001) (Figure 3; Table 2).
Pretreatment of A549 cells with soy isoflavones followed by
radiation and then continued treatment with soy isoflavones
caused a marked augmentation in the formation of DSBs breaks,
which persisted overtime. The mean number of -H2AX foci
per cell and per field was much greater than with soy isoflavones
alone (p 0.001) or radiation alone (p 0.001) when measured
at 1 hour after radiation in cells treated with soy isoflavones and
radiation (p 0.05) (Table 2). More than 90% of the cells were
-H2AX (Figure 3). In contrast to radiation treatment only,
cells treated with soy isoflavones and radiation maintained a
high frequency of more than 70% -H2AX cells at 24 hours
after radiation (Figure 3). These cells also showed high numbers
of foci per cell and per field compared with 24 hours after
radiation only (p  0.001) (Table 2).
Effect of Soy Isoflavones Combined with
Radiation on Expression of -H2AX and HIF-1
Proteins Measured by Western Blot Analysis
To measure the expression of -H2AX in whole cell
extracts, repeated experiments, identical to those described
above in Figure 3, were performed. A549 cells were pre-
treated with soy isoflavones at 30 M for 24 hours and then
irradiated with 3 Gy. After further incubation for 1 hour and
24 hours after radiation, corresponding to 24 and 48 hours
treatment with soy respectively, cells were processed for
Western blot analysis to detect -H2AX. Levels of -H2AX
protein were increased by either soy isoflavones or radiation
treatments and were greater in cells treated with the combined
soy isoflavones/radiation when measured 1 hour after radia-
tion (Figure 4). Nevertheless, by 24 hours after radiation,
expression of -H2AX protein decreased in cells treated with
radiation alone but was still persistent in cells treated with soy
isoflavones (Figure 4). These results, obtained by measuring
the total expression of -H2AX in whole cell protein extracts,
confirm the findings observed by immunostaining (Figure 3).
In the same series of experiments, HIF-1 expression was
enhanced by radiation but decreased by soy isoflavones
treatment. Pretreatment of the cells with soy isoflavones
before radiation blocked the up-regulation of HIF-1 expres-
sion induced by radiation (Figure 4).
Radiation-Induced APE1/Ref-1 Expression and
DNA-Binding Activity of Transcription Factors
are Inhibited by Soy Isoflavones
To assess the effect of soy on molecular survival
pathways activated by radiation, cells were pretreated with
TABLE 1. Inhibition of H1650 Cell Growth by Soy
Isoflavones Combined with Radiation In Vitro
Treatment
Mean No. of Cells  105
(Mean  SD)
% Inhibition
(Mean  SD)
Control 7.5  0.42 0
Soy isoflavones (10 M) 5.5  0.14a 27  1
Soy isoflavones (25 M) 3.2  0.28a 57  3
Radiation (3 Gy) 5.2  0.28a 31  4
Soy (10 M)  Rad 3.5  0.42a 54  6
Soy (25 M)  Rad 1.7  0.00b 78  0
H1650 human lung carcinoma cells were plated at 0.6  105 cells/well in six-well
plates. Cells were pretreated for 24 h with soy isoflavones at 10 or 25 M, then
irradiated with 3 Gy, and cultured for 72 h. Viable cells were counted. The mean number
of cells and percent inhibition were calculated from duplicate wells.
a p  0.05.
b p  0.001 compared with control.
FIGURE 3. Increased DNA double-strand breaks in A549
cells treated with soy and radiation. A549 cells were treated
with soy at 30 M for 24 hours then irradiated with 3 Gy
and tested at 1 hour and 24 hours after radiation, corre-
sponding to 24 and 48 hours of soy treatment, respectively.
Control cells (con), cells treated with soy (soy), cells treated
with radiation (Rad), and both combined (Soy  Rad) were
processed for immunostaining of -H2AX to detect DNA
double-strand breaks (DSBs). A, -H2AX staining at 1 hour
after radiation or 24 hours after soy treatment. B, -H2AX
staining at 24 hours after radiation or 48 hours after soy
treatment.
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soy isoflavones (30 M) for 72 hours and then irradiated with
3 Gy. Five hours after radiation, nuclear extracts were either
subjected to Western blot to measure APE1/Ref-1 expression
or to EMSA to determine the DNA-binding activities of
HIF-1 and NF-B transcription factors. A549 cells showed
substantial nuclear expression of APE1/Ref-1, but it was
significantly down-regulated by soy isoflavones treatment
(p  0.001). Nevertheless, APE1/Ref-1 was significantly
up-regulated by radiation (p  0.001) (Figure 5A). The
radiation-induced increase of APE1/Ref-1 expression was
inhibited by pretreatment with soy isoflavones, resulting in a
significant APE1/Ref-1 decrease in soy isoflavones  radia-
tion compared with radiation alone (p  0.001) as analyzed
by the band density (I.D.V. diagrams, Figure 5A). Soy iso-
flavones also inhibited HIF-1 DNA-binding activity and the
increase induced by radiation (p  0.001) (Figure 5B).
A549 cells were found to express a low level of NF-B
DNA-binding activity, which was significantly augmented
by radiation (p  0.001) (Figure 5C). Soy isoflavones
decreased significantly the baseline level of NF-B DNA-
binding activity (p  0.001, compared with control) (Fig-
ure 5C). Pretreatment with soy isoflavones significantly
attenuated the radiation-induced DNA-binding activity of
NF-B (p  0.001). The NF-B activity level of soy
isoflavones  radiation-treated cells showed a baseline
level comparable with that of control cells (p  0.05)
(I.D.V. diagrams, Figure 5C).
Effect of APE1/Ref-1 Inhibitors on DNA Repair
and Cell Killing
As shown in Figure 5A, soy inhibits the radiation-
induced up-regulation of both the DNA repair enzyme APE1/
Ref-1 and NF-B DNA-binding activity. APE1/Ref-1 has
dual functions as a DNA repair enzyme and as a redox
activator of transcription factors, including NF-B and HIF-
1. To determine whether soy-mediated decrease of APE1/
Ref-1 expression is involved in the mechanism of soy inhi-
bition of DNA repair, we tested two different APE1/Ref-1
inhibitors, E3330 and methoxyamine. E3330 inhibits the
redox activity of APE1/Ref-1, whereas methoxyamine inhib-
its the DNA repair activity of APE1/Ref-1.26 A549 cells were
pretreated with E3330 (50 M), methoxyamine (20 mM), or
soy isoflavones (30 M) for 24 hours and then irradiated at 3
Gy. Cells were further incubated for 1 hour and 24 hours after
radiation, and then processed for -H2AX immunostaining.
This experiment confirmed that radiation caused numerous
-H2AX foci detectable after 1 hour, but the number of foci
and frequency of positive cells were markedly decreased at
24 hours after radiation (Figures 6A, B). Soy isoflavones
combined with radiation caused an increase in -H2AX foci,
which were maintained at 24 hours (Figures 6A, B). Cells
treated with E3330 and radiation showed a pattern of increase
in the number of -H2AX foci and frequency of positive cells
at 1 hour after radiation and a marked decrease at 24 hours
after radiation, which was comparable with that of cells
treated with radiation alone (Figures 6A, B). These data show
that E3330, which inhibits the redox activity of APE1/Ref-1,
did not alter the repair of radiation-induced DSBs over time.
In contrast, cells treated with methoxyamine and radiation
showed a smaller decrease in -H2AX foci at 24 hours after
radiation than that observed with radiation alone (p  0.001)
(Figure 6A). The percent of cells positive for -H2AX foci
remained elevated compared with radiation alone (p 0.001)
(Figure 6B). Thus, methoxyamine, which inhibits the DNA
repair activity of APE1/Ref-1, partially blocked the decrease
in radiation-induced DSBs at 24 hours.
To investigate whether APE1/Ref-1 inhibitors have an
effect on cell growth and cytotoxic activity of soy and
TABLE 2. Quantitative Data Analysis of Formation of -H2AX
Foci in A549 Cells Treated with Soy and Radiation
Treatment
-H2AX
Foci/Cella
(Mean  SD)
-H2AX
Foci/Fieldb
(Mean  SD)
-H2AX
Cells/Fieldc
(Mean %  SD)
Control 0.31  0.25 16  13 7.4  3.2
Soy (24 h) 4.96  1.02 248  51 44.7  8.3
Soy (48 h) 11.77  1.77 589  89 68.8  6.3
Rad (1 h) 13.86  2.31 693  115 86.8  5.8
Rad (24 h) 1.17  0.42 59  21 15.3  4.9
Rad (1 h) 
Soy (24 h)
21.15  2.38 1058  119 93.7  4.5
Rad (24 h) 
Soy (48 h)
12.38  4.13 619  207 72  8.3
The formation of -H2AX fluorescent foci, indicative of DNA DSBs breaks,
obtained in cells treated with soy, radiation, and both combined (as described in Figure
3) was quantitated using Image-pro analysis to determine the following parameters.
a -H2AX foci/cell (mean  SD): the mean number of -H2AX foci per cell was
obtained by image analysis for 400 fields and averaged for five different fields of the
immunostained slide for each treatment.
b -H2AX foci/field (mean SD): the total number of -H2AX foci per400 field
was normalized to 50 cells/field. The mean total number of -H2AX foci  SD was
averaged from five different fields for each treatment.
c -H2AX cells/field (mean %  SD): the percent of -H2AX-positive cells
(-H2AX) per 400 field was calculated for five different fields, and the mean  SD
is reported.
DSB, double-strand break.
FIGURE 4. Effect of soy and radiation on HIF-1 and
-H2AX in A549 cells. Cells were either untreated (Con for
control) or pretreated with 30 M soy, 3 Gy radiation (Rad),
or combined (Soy  Rad). Cells were pretreated with soy for
24 hours, and then cells were irradiated. At 1 hour or 24
hours post radiation, corresponding to 24 and 48 hours soy
treatment, cells were processed for Western blot analysis to
detect -H2AX and HIF-1. -Actin protein levels served as a
loading control.
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radiation, the short-term effect of APE1/Ref-1 inhibitors
alone and combined with soy isoflavones and/or radiation
was tested in A549 cells. Cells were pretreated with E3330,
methoxyamine, soy isoflavones, or in combination for 24
hours and then irradiated with 3 Gy. Cell growth was as-
sessed by counting viable cells at 3 days after radiation.
E3330 did not affect cell growth (p  0.70), whereas me-
thoxyamine significantly inhibited cell growth (p  0.05) by
46% compared with control cells (Figure 7). E3330, which
inhibits the redox activity of APE1/Ref-1, augmented the
inhibition of cell growth mediated by soy (p  0.05) but did
not affect the radiation-induced cell killing (p  0.40). A
drastic decrease in cell growth was observed when methoxy-
amine, which inhibits the DNA repair activity of APE1/
Ref-1, was combined with soy (p  0.005). Methoxyamine
also augmented radiation-induced cell killing (p  0.05) that
was comparable with the effect of soy combined with radia-
tion (approximately 60% inhibition). Addition of methoxy-
amine to soy and radiation caused a further significant inhi-
bition to 80% in cell growth compared with soy  radiation
(p  0.05), whereas insignificant effect was observed with
E3330  soy  radiation compared with soy  radiation
(p  0.13).
DISCUSSION
In this study, the potential of soy isoflavones to enhance
the therapeutic effect of RT for patients with NSCLC was
investigated. Our clinical goals are to design a therapeutic
approach to boost the success of RT in NSCLC using com-
plementary treatment with soy isoflavones, which are non-
toxic natural compounds. Our preclinical and clinical studies,
and others have shown that soy isoflavones not only can act
as anticancer agents but also act as antioxidants in normal
FIGURE 5. Pretreatment with soy inhibits APE-1/Ref-1 expression and HIF-1 and NF-B DNA-binding activity induced by
radiation. A549 cells were pretreated with 30 M soy for 72 hours then irradiated at 3 Gy. At 5 hours after radiation, nuclear
extracts were subjected to Western blot analysis or electrophoretic mobility shift assay (EMSA). Untreated control (Con), soy
alone (Soy), radiation 3 Gy (Rad), and soy combined with radiation (Soy  Rad). A, Nuclear expression of APE1/Ref-1. Nuclear
extracts (10 g) were run on 10% Western gel and blotted against APE-1/Ref-1 Ab. B, HIF-1 DNA-binding activity. Nuclear
extracts were incubated with IRDye-700-labeled HIF-1 oligonucleotide and subjected to EMSA. C, NF-B DNA-binding activ-
ity. Nuclear extracts were incubated with IRDye-700-labeled NF-B oligonucleotide and subjected to EMSA. In panels A, B,
and C, data are also presented as the mean integrated density value (I.D.V.) of the band/g protein loaded (SE). *p  0.05
and ** p 0.001 represent significance of each treatment group relative to control group. Dotted lines and p values in I.D.V.
diagrams show the difference between cells treated with radiation  soy versus radiation only. Western blot for retinoblas-
toma (Rb) protein in the nuclear extract was performed as an internal loading control.
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tissues and protect them from treatment toxicity.15,16,26 More-
over, we have demonstrated that soy isoflavones can act as
radiosensitizers by enhancing radiation-induced cell killing in
various tumor cell lines in vitro5–10 and in vivo.7,8,10–14 Soy
isoflavones could be an ideal complementary approach for
combination with RT for NSCLC, with the potential to
increase the response of the tumor while simultaneously
attenuating normal tissue toxicity.
Soy isoflavones inhibited A549 cell growth and poten-
tiated the effects of radiation, corroborating our previous
findings in PC-3 prostate cancer cells.7,8,10 Treatment of A549
cells with soy isoflavones and radiation showed that soy
isoflavones significantly enhanced the cell killing induced by
radiation. Further data analysis indicated that this effect was
synergistic. These findings in the A549 (wtEGFR; mutKRAS)
cell line were also reproduced in the H1650 (mutEGFR;
wtKRAS) human lung cancer cell line. Therefore, we con-
clude that soy isoflavones are potent anticancer agents that act
as radiosensitizers in human NSCLC cell lines, regardless of
their EGFR and KRAS mutation status.
We previously reported that genistein, the major bio-
active compound of soy isoflavones, inhibited DNA synthe-
sis, as measured by [3H] thymidine uptake, in PC-3 cells.5
Genistein also augmented the DNA synthesis inhibition me-
diated by radiation and arrested cells in the G2/M cell cycle
phase.5 To further investigate the effect of soy isoflavones
and/or radiation on cellular DNA, A549 cells were tested for
-H2AX foci.21,22 Formation of -H2AX foci occurs within
minutes after production of DSBs by ionizing radiation, and
the loss of -H2AX foci after several hours can be attributed
to DNA repair enzymes.21,22 After 3 Gy radiation, a large
number of -H2AX foci occurred by 1 hour but drastically
decreased at 24 hours after radiation, suggesting that A549
cells activated DNA repair mechanisms. Interestingly, we
found that soy isoflavones also cause DSBs. Nevertheless, in
contrast to radiation, the number of -H2AX foci increased
and persisted over time in soy isoflavones pretreated cells,
probably interfering with DNA repair mechanisms. Impor-
tantly, the combination of soy isoflavones and radiation
caused an increase in frequency and intensity of -H2AX
foci, which were maintained at 24 hours, indicating both
increased DNA damage and inhibition of repair. These data
were confirmed by measuring the total expression of -H2AX
in whole cell protein extracts by Western blot. Our findings
on induction and kinetics of DSBs formation by soy isofla-
vones suggest that soy isoflavones disrupts DNA repair pro-
cesses and potentially sensitizes NCSLC to the cytotoxic
effect of radiation. These results were correlated with the
increased cell killing observed in clonogenic assays. Further-
more, these data were also consistent with the inhibition of
the radiation-induced up-regulation of the DNA repair en-
zyme APE1/Ref-1 by soy isoflavones in A549 cells, which
could contribute to alterations in DNA repair mechanisms. In
contrast, cells treated with radiation alone showed a signifi-
cant increase in APE1/Ref-1 within 5 hours after radiation,
which could be associated with the loss of -H2AX foci.
Soy isoflavones enhanced radiation-induced killing by
inhibiting cell survival pathways activated by radiation in-
cluding the repair enzyme/redox activator APE1/Ref-1 and
the transcription factors HIF-1 and NF-B.7–10 In addition
to its effects as a DNA repair enzyme, APE1/Ref-1 functions
as a redox activator of cellular transcription factors including
NF-B and HIF-1 and facilitate their DNA binding by the
reduction of a cysteine residue to a sulfhydryl state.14 We
previously reported a crosstalk between APE1/Ref-1, NF-B,
and HIF-1 molecules by gene transfection studies.14 We and
FIGURE 6. Effect of APE1/Ref-1 inhibitors on -H2AX ex-
pression in A549 cells. A549 cells were pretreated with
E3330 (50 M), methoxyamine (20 mM), or soy isoflavones
(30 M) for 24 hours and then irradiated at 3 Gy. Cells were
further incubated for 1 hour and 24 hours after radiation
and then processed for -H2AX immunostaining. Control
cells (Control), cells treated with radiation (Rad) and both
combined (Soy  Rad), and cells treated with E3330 and
radiation (E3330  Rad) or methoxyamine and radiation
(Methox  Rad) were processed for immunostaining of
-H2AX to detect DNA double-strand breaks (DSBs). A,
Mean number of -H2AX foci per cell. B, Mean percent of
-H2AX-positive cells per field. In both (A) and (B) panels,
bars represent the mean values  SD calculated from three
different fields.
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others have shown that APE1/Ref-1, NF-B, and HIF-1
molecules are up-regulated and/or activated by radiation, and
these molecular events have been implicated in radioresis-
tance of cancer cells.7–10,14,26,27 Expression and/or activities
of these molecules are inhibited by soy isoflavones.7–10 These
findings are consistent with our current results in A549
NSCLC cells. Pretreatment of A549 cells with soy isofla-
vones inhibited the up-regulation of APE1/Ref-1 and HIF-1
expressions induced by radiation. A549 NSCLC showed a
basal level of HIF-1 and NF-B DNA-binding activities that
was decreased by soy isoflavones treatment but increased by
radiation. Soy isoflavones attenuated the up-regulation of
DNA-binding activities of these two transcription factors, as
previously observed in prostate cancer cell lines.7–10
To determine whether soy-mediated decrease of APE1/
Ref-1 expression is involved in the mechanism of soy inhi-
bition of DNA repair, we further tested two different APE1/
Ref-1 inhibitors, E3330 and methoxyamine.26 E3330, which
inhibits the redox activity of APE1/Ref-1,26 did not alter the
repair of radiation-induced DSBs over time. Nevertheless,
methoxyamine, which inhibits the DNA repair activity of
APE1/Ref-1,26 partially blocked the decrease in radiation-
induced DSBs at 24 hours. These data indicate partial miti-
gation of radiation-induced DNA repair by methoxyamine
akin to the effect of soy when it is combined with radiation.
Interestingly, cytotoxic assays showed that methoxyamine
augmented radiation-induced cell killing that was comparable
with the effect of soy combined with radiation, in support
with our findings on inhibition of DNA repair. Methoxy-
amine also increased cell killing mediated by soy isoflavones
and that by soy combined with radiation, suggesting that
additional DNA repair inhibition of APE1/Ref-1 results in
further cell killing. On the other hand, E3330, which inhibits
the redox activity of APE1/Ref-1, did not affect radiation-
induced cell killing that is consistent with its lack of effect on
DNA repair. E3330 did augment the inhibition of cell growth
mediated by soy corroborating our findings that soy inhibits
APE1/Ref-1 and the transcription factors HIF-1 and NF-B.
Our findings suggest that inhibition of APE1/Ref-1
DNA repair activity by soy is involved in the mechanism by
which soy inhibits DNA repair and leads to greater cell
killing in NSCLC cells. This complementary approach, using
safe dietary compounds to enhance the efficacy of RT, seems
to be very promising for designing novel clinical strategies for
optimizing the treatment outcome of patients with NSCLC.
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